OBJECTIVES: Knee cartilage damage is a common cause of referral for orthopedic surgery. Treatment aims to reduce pain and symptoms by repairing cartilage. Microfracture, the current standard of care, yields good short-term clinical outcomes; however, treatment might fail after 2-3 years. A Chitosan-Beta glycerolphosphate-based medical device (BST-CarGel) is used as an adjunct to microfracture and demonstrates improvements in quantity and quality of repaired tissue, potentially reducing the risk of treatment failure. This study aimed to establish the economic value of BST-CarGel vs microfracture alone in knee cartilage repair from the societal perspective, using Germany as the reference market. METHODS: A decision tree with a 20-year time-horizon was constructed, in which undesirable clinical events were inferred following initial surgery. These events consisted of pain management, surgery, and total knee replacement. Clinical outcomes were taken from the pivotal clinical trial, supplemented by other literature. Data and assumptions were validated by a Delphi panel. All relevant resource use and costs for procedures and events were considered. RESULTS: In a group of patients with all lesion sizes, the model inferred that BST-CarGel yields a positive return on investment at year 4 (with 20-year cumulative cost savings of €6448). Reducing the incremental risk of treatment failure gap between the device and microfracture by 25-50% does not alter this conclusion. Cost savings are greatest for patients with large lesions; results for patients with small lesions are more modest. LIMITATIONS: Clinical evidence for microfracture and other interventions varies in quality. Comparative long-term data are lacking. The comparison is limited to microfracture and looks only at costs without considering quality-of-life. CONCLUSION: BST-CarGel potentially represents a cost-saving alternative for patients with knee cartilage injury by reducing the risk of clinical events through regeneration of chondral tissue with hyaline characteristics. Since the burden of this condition is high, both to the patient and society, an effective and economically viable alternative is of importance.
OBJECTIVES: Knee cartilage damage is a common cause of referral for orthopedic surgery. Treatment aims to reduce pain and symptoms by repairing cartilage. Microfracture, the current standard of care, yields good short-term clinical outcomes; however, treatment might fail after 2-3 years. A Chitosan-Beta glycerolphosphate-based medical device (BST-CarGel) is used as an adjunct to microfracture and demonstrates improvements in quantity and quality of repaired tissue, potentially reducing the risk of treatment failure. This study aimed to establish the economic value of BST-CarGel vs microfracture alone in knee cartilage repair from the societal perspective, using Germany as the reference market. METHODS: A decision tree with a 20-year time-horizon was constructed, in which undesirable clinical events were inferred following initial surgery. These events consisted of pain management, surgery, and total knee replacement. Clinical outcomes were taken from the pivotal clinical trial, supplemented by other literature. Data and assumptions were validated by a Delphi panel. All relevant resource use and costs for procedures and events were considered. RESULTS: In a group of patients with all lesion sizes, the model inferred that BST-CarGel yields a positive return on investment at year 4 (with 20-year cumulative cost savings of €6448). Reducing the incremental risk of treatment failure gap between the device and microfracture by 25-50% does not alter this conclusion. Cost savings are greatest for patients with large lesions; results for patients with small lesions are more modest. LIMITATIONS: Clinical evidence for microfracture and other interventions varies in quality. Comparative long-term data are lacking. The comparison is limited to microfracture and looks only at costs without considering quality-of-life. CONCLUSION: BST-CarGel potentially represents a cost-saving alternative for patients with knee cartilage injury by reducing the risk of clinical events through regeneration of chondral tissue with hyaline characteristics. Since the burden of this condition is high, both to the patient and society, an effective and economically viable alternative is of importance.
Authors: Øystein Øvrebø; Giuseppe Perale; Jonathan P Wojciechowski; Cécile Echalier; Jonathan R T Jeffers; Molly M Stevens; Håvard J Haugen; Filippo Rossi Journal: Bioeng Transl Med Date: 2022-03-15
Authors: Qingqiang Yao; Bo Wei; Nancy Liu; Chenshuang Li; Yang Guo; Arya Nick Shamie; James Chen; Cheng Tang; Chengzhe Jin; Yan Xu; Xiuwu Bian; Xinli Zhang; Liming Wang Journal: Tissue Eng Part A Date: 2015-04 Impact factor: 3.845
Authors: Armin Arshi; Peter D Fabricant; Derek E Go; Riley J Williams; David R McAllister; Kristofer J Jones Journal: Cartilage Date: 2017-12-15 Impact factor: 4.634
Authors: Elizaveta Kon; Giuseppe Filardo; Jonathan Shani; Nir Altschuler; Andrew Levy; Ken Zaslav; John E Eisman; Dror Robinson Journal: J Orthop Surg Res Date: 2015-05-28 Impact factor: 2.359
Authors: Markus M Schreiner; Marcus Raudner; Pavol Szomolanyi; Kitty Ohel; Livnat Ben-Zur; Vladimir Juras; Vladimir Mlynarik; Reinhard Windhager; Siegfried Trattnig Journal: Cartilage Date: 2020-06-04 Impact factor: 4.634